Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. (Q38241395)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

metastatic colon cancer

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Christos S Karapetis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Dirk Arnold

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Peter Gibbs

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Timothy J Price

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Matthew Burge

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Daniel G Haller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Niall C Tebbutt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Cornelis J A Punt

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Nick Pavlakis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Jeremy D Shapiro

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

20 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

13 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

1477-1493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

13 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

The continuum of care: a paradigm for the management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Curative strategies for liver metastases from colorectal cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

The role of chemotherapy in managing patients with resectable liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

"Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Gastrointestinal cancer and brain metastasis: a rare and ominous sign

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Changing patterns of bone and brain metastases in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

MEK and RAF inhibitors for BRAF-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

South Australian clinical registry for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.949678

10.1586/14737140.2014.949678

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25138900%20AND%20SRC:MED&resulttype=core&format=json

release_owuc7lzicnahbdm7fbve6iofxq

13 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/owuc7lzicnahbdm7fbve6iofxq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference